The triterpenoid cucurbitacin B augments the antiproliferative activity of chemotherapy in human breast cancer

International Journal of Cancer

Volumn 132, Issue 12, 2013, Pages 2730-2737

  Aribi, Ahmed ^a   Gery, Sigal ^a   Lee, Dhong Hyun ^a   Thoennissen, Nils H ^a   Thoennissen, Gabriela B ^a   Alvarez, Rocio ^a   Ho, Quoc ^a   Lee, Kunik ^a   Doan, Ngan B ^a   Chan, Kin T ^b   Toh, Melvin ^b   Said, Jonathan W ^a   Koeffler, H Phillip ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b (Holdings) Inc   (Hong Kong)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

breast cancer; chemotherapy; cucurbitacin B

Indexed keywords

ANTINEOPLASTIC AGENT; CUCURBITACIN B; DOCETAXEL; GEMCITABINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; MITOSIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BONE MARROW CELLS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; DRUG SYNERGISM; FEMALE; HUMANS; MICE; TAXOIDS; TRITERPENES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84876151515     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27950     Document Type: Article

References (36)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Montero A, Fossella F, Hortobagyi G, et al. Docetaxel for treatment of solid tumours: a systematic review of clinical data [Review]. Lancet Oncol 2005; 6: 229-39.
3. Harvey V, Mouridsen H, Semiglazov V, et al. Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J Clin Oncol 2006; 24: 4963-70.
4. Carmichael J, Possinger K, Phillip P, et al. Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 1995; 13: 2731-6.
5. Chew HK, Doroshow JH, Frankel P, et al. Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer. J Clin Oncol 2009; 27: 2163-9.
6. Tannin-Spitz T, Grossman S, Dovrat S, et al. Growth inhibitory activity of cucurbitacin glucosides isolated from Citrullus colocynthis on human breast cancer cells. Biochem Pharmacol 2007; 73: 56-67.
7. Wakimoto N, Yin D, O'Kelly J, et al. Cucurbitacin B has a potent antiproliferative effect on breast cancer cells in vitro and in vivo. Cancer Sci 2008; 99: 1793-7.
8. Thoennissen NH, Iwanski GB, Doan NB, et al. Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells. Cancer Res 2009; 69: 5876-84.
9. Iwanski GB, Lee DH, En-Gal S, et al. Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer. Br J Pharmacol 2010; 160: 998-1007.
10. Zhang M, Sun C, Shan X, et al. Inhibition of pancreatic cancer cell growth by cucurbitacin B through modulation of signal transducer and activator of transcription 3 signaling. Pancreas 2010; 39: 923-9.
11. Zhang M, Zhang H, Sun C, et al. Targeted constitutive activation of signal transducer and activator of transcription 3 in human hepatocellular carcinoma cells by cucurbitacin B. Cancer Chemother Pharmacol 2009; 63: 635-42.
12. Chan KT, Meng FY, Li Q, et al. Cucurbitacin B induces apoptosis and S phase cell cycle arrest in BEL-7402 human hepatocellular carcinoma cells and is effective via oral administration. Cancer Lett 2010; 294: 118-24.
13. Yin D, Wakimoto N, Xing H, et al. Cucurbitacin B markedly inhibits growth and rapidly affects the cytoskeleton in glioblastoma multiforme. Int J Cancer 2008; 123: 1364-75.
14. Lee DH, Thoennissen NH, Goff C, et al. Synergistic effect of low-dose cucurbitacin B and low-dose methotrexate for treatment of human osteosarcoma. Cancer Lett 2011; 306: 161-70.
15. Chen W, Leiter A, Yin D, et al. Cucurbitacin B inhibits growth, arrests the cell cycle, and potentiates antiproliferative efficacy of cisplatin in cutaneous squamous cell carcinoma cell lines. Int J Oncol 2010; 37: 737-43.
16. Liu T, Zhang M, Zhang H, et al. Combined antitumor activity of cucurbitacin B and docetaxel in laryngeal cancer. Eur J Pharmacol 2008; 10; 587: 78-84.
17. Haritunians T, Gueller S, Zhang L, et al. Cucurbitacin B induces differentiation, cell cycle arrest, and actin cytoskeletal alterations in myeloid leukemia cells. Leuk Res 2008; 32: 1366-73.
18. Chan KT, Li K, Liu SL, et al. Cucurbitacin B inhibits STAT3 and the Raf/MEK/ERK pathway in leukemia cell line K562. Cancer Lett 2010; 289: 46-52.
19. Zhu JS, Ouyang DY, Shi ZJ, et al. Cucurbitacin B induces cell cycle arrest, apoptosis and autophagy associated with G actin reduction and persistent activation of cofilin in Jurkat cells. Pharmacology 2012; 89: 348-6.
20. Chou T, Talalay P,. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
21. Jones SE, Savin MA, Holmes FA, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 2006; 24: 5381-7.
22. Albain KS, Nag SM, Calderillo-Ruiz G, et al. Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 2008; 26: 3950-7.
23. Gudena V, Montero AJ, Glück S,. Gemcitabine and taxanes in metastatic breast cancer: a systematic review. Ther Clin Risk Manag 2008; 4: 1157-64.
24. Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008; 358: 1663-71.
25. Chan S, Romieu G, Huober J, et al. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. J Clin Oncol 2009; 27: 1753-60.
26. Roy V, LaPlant B, Gross G, et al. Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531). Ann Oncol 2009; 20: 449-53.
27. Vici P, Giotta F, DI Lauro L, et al. Multicenter phase II trial of first-line docetaxel/gemcitabine in advanced breast cancer pretreated with adjuvant anthracyclines. Anticancer Res 2009; 29: 1841-5.
28. Gajria D, Seidman A, Dang C,. Adjuvant taxanes: more to the story [Review]. Clin Breast Cancer 2010; 10: S41-9.
29. Ginés J, Sabater E, Martorell C, et al. Efficacy of taxanes as adjuvant treatment of breast cancer: a review and meta-analysis of randomised clinical trials [Review]. Clin Transl Oncol 2011; 13: 485-98.
30. Chen JC, Chiu MH, Nie RL, et al. Cucurbitacins and cucurbitane glycosides: structures and biological activities. Nat Prod Rep 2005; 22: 386-99.
31. Duangmano S, Dakeng S, Jiratchariyakul W, et al. Antiproliferative effects of cucurbitacin b in breast cancer cells: down-regulation of the c-Myc/hTERT/telomerase pathway and obstruction of the cell cycle. Int J Mol Sci 2010; 11: 5323-38.
32. Dakeng S, Duangmano S, Jiratchariyakul W, et al. Inhibition of Wnt signaling by cucurbitacin B in breast cancer cells: reduction of Wnt associated proteins and reduced translocation of galectin-3-mediated β-catenin to the nucleus. J Cell Biochem 2012; 113: 49-60.
33. Duangmano S, Sae-Lim P, Suksamrarn A, et al. Cucurbitacin B causes increased radiation sensitivity of human breast cancer cells via G2/M cell cycle arrest. J Oncol 2012; 2012: 601682.
34. Mansilla S, Llovera L, Portugal J,. Chemotherapeutic targeting of cell death pathways. Anticancer Agents Med Chem 2012; 12: 226-38.
35. Jin HR, Jin X, Dat NT, et al. Cucurbitacin B suppresses the transactivation activity of RelA/p65. J Cell Biochem 2011; 112: 1643-50.
36. Chang GC, Hsu SL, Tsai JR, et al. Extracellular signal-regulated kinase activation and Bcl-2 downregulation mediate apoptosis after gemcitabine treatment partly via a p53-independent pathway. Eur J Pharmacol 2004; 502: 169-83.